Lindstrom M, DeCleene N, Dorsey H, Fuster V, Johnson CO, LeGrand KE, et al. Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021. J Am Coll Cardiol. 2022;80(25):2372-425.

Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021.

Collaborators GBDF. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2204-56.

Chong B, Jayabaskaran J, Jauhari SM, Chan SP, Goh R, Kueh MTW, et al. Global burden of cardiovascular diseases: projections from 2025 to 2050. Eur J Prev Cardiol. 2024.

The top 10 causes of death [Internet]. Geneva: World Health Organization; [updated 7 August 2024. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death.

Salari N, Morddarvanjoghi F, Abdolmaleki A, Rasoulpoor S, Khaleghi AA, Hezarkhani LA, et al. The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2023;23(1):206.

Rittiphairoj T, Bulstra C, Ruampatana C, Stavridou M, Grewal S, Reddy CL, et al. The economic burden of ischaemic heart diseases on health systems: a systematic review. BMJ Glob Health. 2025;10(2).

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). Circulation. 2018;138(20):e618-e51.

Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med. 2017;376(21):2053-64.

Gabriel-Costa D. The pathophysiology of myocardial infarction-induced heart failure. Pathophysiology. 2018;25(4):277-84.

Frantz S, Hundertmark MJ, Schulz-Menger J, Bengel FM, Bauersachs J. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022;43(27):2549-61.

Bostan MM, Statescu C, Anghel L, Serban IL, Cojocaru E, Sascau R. Post-Myocardial Infarction Ventricular Remodeling Biomarkers-The Key Link between Pathophysiology and Clinic. Biomolecules. 2020;10(11).

Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target? Circulation. 2004;109(13):1580-9.

Heusch G, Libby P, Gersh B, Yellon D, Bohm M, Lopaschuk G, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383(9932):1933-43.

Zafari AM, Yang EH. Myocardial Infarction Treatment & Management: Approach Considerations, Prehospital Care and Initial Management, Emergency Department Care and In-Hospital Management: Medscape; [Available from: https://emedicine.medscape.com/article/155919-treatment.

McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365(9474):1877-89.

Frangogiannis NG. Pathophysiology of Myocardial Infarction. Compr Physiol. 2015;5(4):1841-75.

Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006;114(25):2871-91.

Liu T, Hao Y, Zhang Z, Zhou H, Peng S, Zhang D, et al. Advanced Cardiac Patches for the Treatment of Myocardial Infarction. Circulation. 2024;149(25):2002-20.

Garbern JC, Lee RT. Heart regeneration: 20 years of progress and renewed optimism. Dev Cell. 2022;57(4):424-39.

Miller L, Birks E, Guglin M, Lamba H, Frazier OH. Use of Ventricular Assist Devices and Heart Transplantation for Advanced Heart Failure. Circ Res. 2019;124(11):1658-78.

Nakamura M, Huang GN. Why some hearts heal and others don't: The phylogenetic landscape of cardiac regenerative capacity. Semin Cell Dev Biol. 2025;170:103609.

Poss KD, Wilson LG, Keating MT. Heart regeneration in zebrafish. Science. 2002;298(5601):2188-90.

Kikuchi K, Poss KD. Cardiac regenerative capacity and mechanisms. Annu Rev Cell Dev Biol. 2012;28:719-41.

Ma S, Yan J, Chen L, Zhu Y, Chen K, Zheng C, et al. A Bibliometric and Visualized Analysis of Cardiac Regeneration Over a 20-Year Period. Front Cardiovasc Med. 2021;8:789503.

Porrello ER, Mahmoud AI, Simpson E, Hill JA, Richardson JA, Olson EN, et al. Transient regenerative potential of the neonatal mouse heart. Science. 2011;331(6020):1078-80.

Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M, et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature. 2013;493(7432):433-6.

Auchampach J, Han L, Huang GN, Kuhn B, Lough JW, O'Meara CC, et al. Measuring cardiomyocyte cell-cycle activity and proliferation in the age of heart regeneration. Am J Physiol Heart Circ Physiol. 2022;322(4):H579-H96.

Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S, et al. Evidence for cardiomyocyte renewal in humans. Science. 2009;324(5923):98-102.

Riching AS, Song K. Cardiac Regeneration: New Insights Into the Frontier of Ischemic Heart Failure Therapy. Front Bioeng Biotechnol. 2020;8:637538.

Brezitski KD, Goff AW, DeBenedittis P, Karra R. A Roadmap to Heart Regeneration Through Conserved Mechanisms in Zebrafish and Mammals. Curr Cardiol Rep. 2021;23(4):29.

Rolland L, Jopling C. The multifaceted nature of endogenous cardiac regeneration. Front Cardiovasc Med. 2023;10:1138485.

Bertero A, Murry CE. Hallmarks of cardiac regeneration. Nat Rev Cardiol. 2018;15(10):579-80.

Li Z, Hu S, Cheng K. Chemical Engineering of Cell Therapy for Heart Diseases. Acc Chem Res. 2019;52(6):1687-96.

Csobonyeiova M, Beerova N, Klein M, Debreova-Cehakova M, Danisovic L. Cell-Based and Selected Cell-Free Therapies for Myocardial Infarction: How Do They Compare to the Current Treatment Options? Int J Mol Sci. 2022;23(18).

Bar A, Cohen S. Inducing Endogenous Cardiac Regeneration: Can Biomaterials Connect the Dots? Front Bioeng Biotechnol. 2020;8:126.

Carvalho AB, de Carvalho AC. Heart regeneration: Past, present and future. World J Cardiol. 2010;2(5):107-11.

Ali SA, Mahmood Z, Mubarak Z, Asad M, Sarfraz Chaudhri MT, Bilal L, et al. Assessing the Potential Benefits of Stem Cell Therapy in Cardiac Regeneration for Patients With Ischemic Heart Disease. Cureus. 2025;17(1):e76770.

Muller P, Lemcke H, David R. Stem Cell Therapy in Heart Diseases - Cell Types, Mechanisms and Improvement Strategies. Cell Physiol Biochem. 2018;48(6):2607-55.

Pezhouman A, Nguyen NB, Kay M, Kanjilal B, Noshadi I, Ardehali R. Cardiac regeneration - Past advancements, current challenges, and future directions. J Mol Cell Cardiol. 2023;182:75-85.

Braunwald E. Cell-Based Therapy in Cardiac Regeneration: An Overview. Circ Res. 2018;123(2):132-7.

Selvakumar D, Clayton ZE, Chong JJH. Robust Cardiac Regeneration: Fulfilling the Promise of Cardiac Cell Therapy. Clin Ther. 2020;42(10):1857-79.

Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307(16):1717-26.

Martino H, Brofman P, Greco O, Bueno R, Bodanese L, Clausell N, et al. Multicentre, randomized, double-blind trial of intracoronary autologous mononuclear bone marrow cell injection in non-ischaemic dilated cardiomyopathy (the dilated cardiomyopathy arm of the MiHeart study). Eur Heart J. 2015;36(42):2898-904.

Banerjee MN, Bolli R, Hare JM. Clinical Studies of Cell Therapy in Cardiovascular Medicine: Recent Developments and Future Directions. Circ Res. 2018;123(2):266-87.

Zhang JJ, Pogwizd SM, Fukuda K, Zimmermann WH, Fan C, Hare JM, et al. Trials and tribulations of cell therapy for heart failure: an update on ongoing trials. Nat Rev Cardiol. 2025;22(5):372-85.

Margiana R, Markov A, Zekiy AO, Hamza MU, Al-Dabbagh KA, Al-Zubaidi SH, et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res Ther. 2022;13(1):366.

Gupta S, Sharma A, S A, Verma RS. Mesenchymal Stem Cells for Cardiac Regeneration: from Differentiation to Cell Delivery. Stem Cell Rev Rep. 2021;17(5):1666-94.

Zhu D, Cheng K. Cardiac Cell Therapy for Heart Repair: Should the Cells Be Left Out? Cells. 2021;10(3).

Huang K, Hu S, Cheng K. A New Era of Cardiac Cell Therapy: Opportunities and Challenges. Adv Healthc Mater. 2019;8(2):e1801011.

Mathiasen AB, Qayyum AA, Jorgensen E, Helqvist S, Kofoed KF, Haack-Sorensen M, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with ischaemic heart failure: final 4-year follow-up of the MSC-HF trial. Eur J Heart Fail. 2020;22(5):884-92.

Heldman AW, DiFede DL, Fishman JE, Zambrano JP, Trachtenberg BH, Karantalis V, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62-73.

Patel AN, Henry TD, Quyyumi AA, Schaer GL, Anderson RD, Toma C, et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016;387(10036):2412-21.

Bolli R, Mitrani RD, Hare JM, Pepine CJ, Perin EC, Willerson JT, et al. A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail. 2021;23(4):661-74.

Bartolucci J, Verdugo FJ, Gonzalez PL, Larrea RE, Abarzua E, Goset C, et al. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]). Circ Res. 2017;121(10):1192-204.

Seyihoglu B, Orhan I, Okudur N, Aygun HK, Bhupal M, Yavuz Y, et al. 20 years of treating ischemic cardiomyopathy with mesenchymal stromal cells: a meta-analysis and systematic review. Cytotherapy. 2024;26(12):1443-57.

Abouzid MR, Umer AM, Jha SK, Akbar UA, Khraisat O, Saleh A, et al. Stem Cell Therapy for Myocardial Infarction and Heart Failure: A Comprehensive Systematic Review and Critical Analysis. Cureus. 2024;16(5):e59474.

Nussbaum J, Minami E, Laflamme MA, Virag JA, Ware CB, Masino A, et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J. 2007;21(7):1345-57.

Wang J, An M, Haubner BJ, Penninger JM. Cardiac regeneration: Options for repairing the injured heart. Front Cardiovasc Med. 2022;9:981982.

Menasche P, Vanneaux V, Hagege A, Bel A, Cholley B, Parouchev A, et al. Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. J Am Coll Cardiol. 2018;71(4):429-38.

Wulfse M, Vervoorn MT, Amelink J, Ballan EM, de Jager SCA, Sluijter JPG, et al. Past Trends and Future Directions of Cardiac Regenerative Medicine - A Systematic Analysis of Clinical Trial Registries. J Cardiovasc Transl Res. 2025;18(1):209-20.

Watanabe T, Hatayama N, Guo M, Yuhara S, Shinoka T. Bridging the Gap: Advances and Challenges in Heart Regeneration from In Vitro to In Vivo Applications. Bioengineering (Basel). 2024;11(10).

Pagano F, Picchio V, Chimenti I, Sordano A, De Falco E, Peruzzi M, et al. On the Road to Regeneration: "Tools" and "Routes" Towards Efficient Cardiac Cell Therapy for Ischemic Cardiomyopathy. Curr Cardiol Rep. 2019;21(11):133.

Cambria E, Pasqualini FS, Wolint P, Gunter J, Steiger J, Bopp A, et al. Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types. NPJ Regen Med. 2017;2:17.

Gibbs CE, Marchiano S, Zhang K, Yang X, Murry CE, Boyle PM. Graft-host coupling changes can lead to engraftment arrhythmia: a computational study. J Physiol. 2023;601(13):2733-49.

Menasche P. Cell therapy trials for heart regeneration - lessons learned and future directions. Nat Rev Cardiol. 2018;15(11):659-71.

Garry GA, Bassel-Duby R, Olson EN. Direct reprogramming as a route to cardiac repair. Semin Cell Dev Biol. 2022;122:3-13.

Arunadevi N, Jone Kirubavathy S. Three-dimensional approaches based on nanotechnology towards wound management. In: Solanki PR, Kumar A, Pratap Singh R, Singh J, Rb Singh K, editors. Nanotechnological Aspects for Next-Generation Wound Management: Academic Press; 2024. p. 245-80.

Hashimoto H, Olson EN, Bassel-Duby R. Therapeutic approaches for cardiac regeneration and repair. Nat Rev Cardiol. 2018;15(10):585-600.

Segers VF, Lee RT. Protein therapeutics for cardiac regeneration after myocardial infarction. J Cardiovasc Transl Res. 2010;3(5):469-77.

Schumacher B, Stegmann T, Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg (Torino). 1998;39(6):783-9.

Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T, et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science. 1992;257(5075):1401-3.

Rasanen M, Sultan I, Paech J, Hemanthakumar KA, Yu W, He L, et al. VEGF-B Promotes Endocardium-Derived Coronary Vessel Development and Cardiac Regeneration. Circulation. 2021;143(1):65-77.

Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, Su Y, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther. 2009;17(6):1109-15.

Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 2003;107(10):1359-65.

Gao F, Kataoka M, Liu N, Liang T, Huang ZP, Gu F, et al. Therapeutic role of miR-19a/19b in cardiac regeneration and protection from myocardial infarction. Nat Commun. 2019;10(1):1802.

Zhu K, Liu D, Lai H, Li J, Wang C. Developing miRNA therapeutics for cardiac repair in ischemic heart disease. J Thorac Dis. 2016;8(9):E918-E27.

Fang Y, Xu Y, Wang R, Hu L, Guo D, Xue F, et al. Recent advances on the roles of LncRNAs in cardiovascular disease. J Cell Mol Med. 2020;24(21):12246-57.

Dalil D, Bahanesteh A, Rezaei M, Afzali A, Vanaki A, Varamini A. The Role of Long Noncoding RNAs in Cardiomyocyte Proliferation and Heart Regeneration After Myocardial Infarction: A Systematic Review. Cell Transplant. 2024;33:9636897241266725.

Shafei S, Khanmohammadi M, Ghanbari H, Nooshabadi VT, Tafti SHA, Rabbani S, et al. Effectiveness of exosome mediated miR-126 and miR-146a delivery on cardiac tissue regeneration. Cell Tissue Res. 2022;390(1):71-92.

Wei Q, Xiao Y, Du L, Li Y. Advances in Nanoparticles in the Prevention and Treatment of Myocardial Infarction. Molecules. 2024;29(11).

Reiss AB, Ahmed S, Johnson M, Saeedullah U, De Leon J. Exosomes in Cardiovascular Disease: From Mechanism to Therapeutic Target. Metabolites. 2023;13(4).

Sepehri M, Rabbani S, Ai J, Bahrami N, Ghanbari H, Namini MS, et al. Therapeutic potential of exosomes derived from human endometrial mesenchymal stem cells for heart tissue regeneration after myocardial infarction. Regen Ther. 2025;28:451-61.

Menasche P, Renault NK, Hagege A, Puscas T, Bellamy V, Humbert C, et al. First-in-man use of a cardiovascular cell-derived secretome in heart failure. Case report. EBioMedicine. 2024;103:105145.

Adamiak M, Cheng G, Bobis-Wozowicz S, Zhao L, Kedracka-Krok S, Samanta A, et al. Induced Pluripotent Stem Cell (iPSC)-Derived Extracellular Vesicles Are Safer and More Effective for Cardiac Repair Than iPSCs. Circ Res. 2018;122(2):296-309.

Han C, Yang J, Sun J, Qin G. Extracellular vesicles in cardiovascular disease: Biological functions and therapeutic implications. Pharmacol Ther. 2022;233:108025.

Das D, Jothimani G, Banerjee A, Dey A, Duttaroy AK, Pathak S. A brief review on recent advances in diagnostic and therapeutic applications of extracellular vesicles in cardiovascular disease. Int J Biochem Cell Biol. 2024;173:106616.

Talman V, Ruskoaho H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 2016;365(3):563-81.

Ieda M, Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, et al. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell. 2010;142(3):375-86.

Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, et al. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature. 2012;485(7400):593-8.

Sadahiro T, Ieda M. Direct Cardiac Reprogramming for Cardiovascular Regeneration and Differentiation. Keio J Med. 2020;69(3):49-58.

Zhao Y, Londono P, Cao Y, Sharpe EJ, Proenza C, O'Rourke R, et al. High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling. Nat Commun. 2015;6:8243.

Andrianto A, Mulia EPB, Luke K. Direct cardiac reprogramming: basics and future challenges. Mol Biol Rep. 2023;50(1):865-71.

Portillo Esquivel LE, Zhang B. Application of Cell, Tissue, and Biomaterial Delivery in Cardiac Regenerative Therapy. ACS Biomater Sci Eng. 2021;7(3):1000-21.

Sharma V, Dash SK, Govarthanan K, Gahtori R, Negi N, Barani M, et al. Recent Advances in Cardiac Tissue Engineering for the Management of Myocardium Infarction. Cells. 2021;10(10).

Pomeroy JE, Helfer A, Bursac N. Biomaterializing the promise of cardiac tissue engineering. Biotechnol Adv. 2020;42:107353.

Huyer LD, Montgomery M, Zhao Y, Xiao Y, Conant G, Korolj A, et al. Biomaterial based cardiac tissue engineering and its applications. Biomed Mater. 2015;10(3):034004.

Gil-Cabrerizo P, Scacchetti I, Garbayo E, Blanco-Prieto MJ. Cardiac tissue engineering for myocardial infarction treatment. Eur J Pharm Sci. 2023;185:106439.

Tariq U, Gupta M, Pathak S, Patil R, Dohare A, Misra SK. Role of Biomaterials in Cardiac Repair and Regeneration: Therapeutic Intervention for Myocardial Infarction. ACS Biomater Sci Eng. 2022;8(8):3271-98.

Xu Y, Yu Y, Guo Z. Hydrogels in cardiac tissue engineering: application and challenges. Mol Cell Biochem. 2025;480(4):2201-22.

Saludas L, Pascual-Gil S, Prosper F, Garbayo E, Blanco-Prieto M. Hydrogel based approaches for cardiac tissue engineering. Int J Pharm. 2017;523(2):454-75.

Rakshit P, Giri TK, Mukherjee K. Progresses and perspectives on natural polysaccharide based hydrogels for repair of infarcted myocardium. Int J Biol Macromol. 2024;269(Pt 2):132213.

Sun X, Nunes SS. Overview of hydrogel-based strategies for application in cardiac tissue regeneration. Biomed Mater. 2015;10(3):034005.

Zhang X, Zhao G, Ma T, Simmons CA, Santerre JP. A critical review on advances and challenges of bioprinted cardiac patches. Acta Biomater. 2024;189:1-24.

Mei X, Cheng K. Recent Development in Therapeutic Cardiac Patches. Front Cardiovasc Med. 2020;7:610364.

Li M, Wu H, Yuan Y, Hu B, Gu N. Recent fabrications and applications of cardiac patch in myocardial infarction treatment. View. 2021;3(2):20200153.

Liu Z, Zheng Z, Xie J, Wei H, Yu CY. Hydrogel-based cardiac patches for myocardial infarction therapy: Recent advances and challenges. Mater Today Bio. 2024;29:101331.

Panda A, Matadh VA, Suresh S, Shivakumar HN, Murthy SN. Non-dermal applications of microneedle drug delivery systems. Drug Deliv Transl Res. 2022;12(1):67-78.

Lee K, Goudie MJ, Tebon P, Sun W, Luo Z, Lee J, et al. Non-transdermal microneedles for advanced drug delivery. Adv Drug Deliv Rev. 2020;165-166:41-59.

Tang J, Wang J, Huang K, Ye Y, Su T, Qiao L, et al. Cardiac cell-integrated microneedle patch for treating myocardial infarction. Sci Adv. 2018;4(11):eaat9365.

Yuan J, Yang H, Liu C, Shao L, Zhang H, Lu K, et al. Microneedle Patch Loaded with Exosomes Containing MicroRNA-29b Prevents Cardiac Fibrosis after Myocardial Infarction. Adv Healthc Mater. 2023;12(13):e2202959.

Lim S, Park TY, Jeon EY, Joo KI, Cha HJ. Double-layered adhesive microneedle bandage based on biofunctionalized mussel protein for cardiac tissue regeneration. Biomaterials. 2021;278:121171.

Wang Q, Cao S, Zhang T, Lv F, Zhai M, Bai D, et al. Reactive oxide species and ultrasound dual-responsive bilayer microneedle array for in-situ sequential therapy of acute myocardial infarction. Biomater Adv. 2024;162:213917.

Shokraei N, Asadpour S, Shokraei S, Nasrollahzadeh Sabet M, Faridi-Majidi R, Ghanbari H. Development of electrically conductive hybrid nanofibers based on CNT-polyurethane nanocomposite for cardiac tissue engineering. Microsc Res Tech. 2019;82(8):1316-25.

Ahmadi P, Nazeri N, Derakhshan MA, Ghanbari H. Preparation and characterization of polyurethane/chitosan/CNT nanofibrous scaffold for cardiac tissue engineering. Int J Biol Macromol. 2021;180:590-8.

Alvarez-Argote S, O'Meara CC. The Evolving Roles of Cardiac Macrophages in Homeostasis, Regeneration, and Repair. Int J Mol Sci. 2021;22(15).

Suku M, Forrester L, Biggs M, Monaghan MG. Resident Macrophages and Their Potential in Cardiac Tissue Engineering. Tissue Eng Part B Rev. 2022;28(3):579-91.

Wei KH, Lin IT, Chowdhury K, Lim KL, Liu KT, Ko TM, et al. Comparative single-cell profiling reveals distinct cardiac resident macrophages essential for zebrafish heart regeneration. Elife. 2023;12.

Constanty F, Wu B, Wei KH, Lin IT, Dallmann J, Guenther S, et al. Border-zone cardiomyocytes and macrophages regulate extracellular matrix remodeling to promote cardiomyocyte protrusion during cardiac regeneration. Nat Commun. 2025;16(1):3823.

Lafuse WP, Wozniak DJ, Rajaram MVS. Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair. Cells. 2020;10(1).

Molinaro C, Scalise M, Leo I, Salerno L, Sabatino J, Salerno N, et al. Polarizing Macrophage Functional Phenotype to Foster Cardiac Regeneration. Int J Mol Sci. 2023;24(13).

Amaro-Prellezo E, Gomez-Ferrer M, Hakobyan L, Ontoria-Oviedo I, Peiro-Molina E, Tarazona S, et al. Extracellular vesicles from dental pulp mesenchymal stem cells modulate macrophage phenotype during acute and chronic cardiac inflammation in athymic nude rats with myocardial infarction. Inflamm Regen. 2024;44(1):25.

Bakhshian Nik A, Alvarez-Argote S, O'Meara CC. Interleukin 4/13 signaling in cardiac regeneration and repair. Am J Physiol Heart Circ Physiol. 2022;323(5):H833-H44.

Xiao Y, Zhang H, Liu X, Xu P, Du H, Wang J, et al. Medium from human iPSC-derived primitive macrophages promotes adult cardiomyocyte proliferation and cardiac regeneration. Nat Commun. 2025;16(1):3012.

Bai L, Wang Y, Du S, Si Y, Chen L, Li L, et al. Lymphangiogenesis: A new strategy for heart disease treatment (Review). Int J Mol Med. 2024;53(4).

Klaourakis K, Vieira JM, Riley PR. The evolving cardiac lymphatic vasculature in development, repair and regeneration. Nat Rev Cardiol. 2021;18(5):368-79.

Henri O, Pouehe C, Houssari M, Galas L, Nicol L, Edwards-Levy F, et al. Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction. Circulation. 2016;133(15):1484-97; discussion 97.

Keller TCSt, Lim L, Shewale SV, McDaid K, Marti-Pamies I, Tang AT, et al. Genetic blockade of lymphangiogenesis does not impair cardiac function after myocardial infarction. J Clin Invest. 2021;131(20).

Harris NR, Nielsen NR, Pawlak JB, Aghajanian A, Rangarajan K, Serafin DS, et al. VE-Cadherin Is Required for Cardiac Lymphatic Maintenance and Signaling. Circ Res. 2022;130(1):5-23.

Liu X, Cui K, Wu H, Li KS, Peng Q, Wang D, et al. Promoting Lymphangiogenesis and Lymphatic Growth and Remodeling to Treat Cardiovascular and Metabolic Diseases. Arterioscler Thromb Vasc Biol. 2023;43(1):e1-e10.

Wang YC, Meng WT, Zhang HF, Zhu J, Wang QL, Mou FF, et al. Lymphangiogenesis, a potential treatment target for myocardial injury. Microvasc Res. 2023;145:104442.